Xoma Corp Del Com (NASDAQ:XOMA)

CAPS Rating: 1 out of 5

A biopharmaceutical company that discovers, develops and manufactures antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer and infectious diseases.

XOMA News and Commentary

Caps

How do you think XOMA will perform against the market?

Add Stock to CAPS Watchlist

All Players

329 Outperform
50 Underperform
 

All-Star Players

25 Outperform
25 Underperform
 

Wall Street

10 Outperform
1 Underperform
 

Top XOMA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

TMFBiologyFool (67.42)
Submitted March 07, 2014

Knockdown after EOA data looks like a decent entry point.

jed71 (99.84)
Submitted February 01, 2017

I am down-thumbing this completely out of principle. This might run higher against me short term, but I have plenty of patience to wait for this to crater. I have no idea who in the investing community would think that this is a good investment, but… More

XOMA VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about XOMA.

Recs

0
Member Avatar zzlangerhans (99.85) Submitted: 11/24/2017 12:57:58 AM : Underperform Start Price: $27.47 XOMA Score: -17.77

In August Xoma more than doubled after they licensed their albatross lead drug gevokizumab to Novartis for 31M upfront, milestones, and royalties. That was a nice coup considering that gevo had failed multiple indications and was probably being valued at zero. The problem is that the stock has doubled again from there on the back of a lot of hype in Seeking Alpha and elsewhere comparing the company to Ligand before Ligand embarked on 1500% gains a few years back.

Is Xoma the new Ligand? It's rather hard for me to see it considering that gevo wasn't one of a stable of Xoma drugs, but rather their lead drug for years. 31M was a nice cash infusion, even if 5M came in the form of a dilutive equity investment, but I don't think it would be wise to count on Xoma receiving much more from that heavily backloaded deal with Novartis. 31M is a fingernail paring for Novartis, a project for their R&D department to kick around but definitely not a high priority. Meanwhile, it's questionable how much else Xoma has of value. The other recent deals related to phage display libraries have been pretty small potatoes.

I wouldn't dismiss Xoma completely, but I'd want them to prove themselves before buying into all this hype. Once the current injection of helium has dissipated, expect Xoma stock to descend if the company doesn't deliver soon with new deals and profitable quarters.

Recs

0
Member Avatar AnsgarJohn (99.12) Submitted: 11/15/2017 5:59:15 PM : Underperform Start Price: $26.51 XOMA Score: -21.01

Whatsthepoint

Recs

0
Member Avatar RES7 (98.84) Submitted: 3/9/2017 12:05:43 AM : Underperform Start Price: $5.34 XOMA Score: -504.67

jed71

Leaderboard

Find the members with the highest scoring picks in XOMA.

Score Leader

hayrettin

hayrettin (70.49) Score: +481.83

The Score Leader is the player with the highest score across all their picks in XOMA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
This player feels very strongly about this pick and has marked it a Top Pick. Top Picks do not affect a player’s score. hayrettin 70.49 2/28/2017 Outperform 5Y $4.82 +583.61% +12.33% +571.28 0 Comment
RUNNER71 70.03 10/25/2016 Outperform 1Y $5.34 +517.04% +24.13% +492.91 0 Comment
BigDreamer 56.95 4/17/2017 Outperform NS $6.57 +401.52% +14.10% +387.42 0 Comment
tarikny500 < 20 8/1/2017 Outperform 5Y $7.21 +357.00% +7.48% +349.52 0 Comment
jdbenham < 20 8/25/2006 Underperform NS $516.00 -93.61% +118.83% +212.45 0 Comment
tmhuston 69.41 3/13/2008 Underperform 1Y $732.00 -95.50% +113.87% +209.37 0 Comment
fiuser < 20 1/22/2008 Underperform 3M $810.00 -95.93% +111.94% +207.87 0 Comment
drakitin 99.59 8/15/2008 Underperform 1Y $702.00 -95.31% +110.54% +205.84 0 Comment
stockomatico < 20 10/2/2006 Underperform 1Y $570.00 -94.22% +111.45% +205.67 0 Comment
njwillie1 95.41 9/29/2006 Underperform 3M $546.00 -93.97% +111.20% +205.17 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackJimCramer 85.11 6/25/2015 Underperform 3W $81.40 -59.52% +26.76% +86.28 0 Comment
TrackCreditSuiss 90.59 11/13/2012 Outperform NS $55.60 -40.74% +93.38% -134.12 0 Comment
TrackZacks < 20 7/6/2012 Underperform 3M $76.60 -19.58% +3.82% +23.40 8/23/2012 @ $61.60 1 Comment
TrackRothCapital 71.17 6/28/2012 Outperform NS $61.80 -46.68% +101.06% -147.74 0 Comment
TrackCowenandCo 86.03 5/14/2012 Outperform NS $54.20 -39.21% +98.03% -137.24 0 Comment
trackmlvcapital < 20 3/31/2011 Outperform NS $57.80 -42.99% +100.59% -143.58 0 Comment
TrackZacks < 20 1/6/2011 Outperform 3M $135.60 -65.78% +10.24% -76.03 3/20/2012 @ $46.40 1 Comment
TrackWedbush 87.15 1/4/2011 Outperform NS $127.20 -74.10% +110.71% -184.81 0 Comment
TrackPacificGrow < 20 7/29/2008 Outperform NS $582.00 -91.17% +11.32% -102.49 4/17/2012 @ $51.40 0 Comment
TrackSusquehanna 93.59 5/13/2008 Outperform NS $645.00 -94.89% +96.47% -191.36 0 Comment
TrackLadenburg < 20 5/12/2008 Outperform NS $642.00 -94.87% +96.56% -191.43 0 Comment
TrackPZK < 20 3/25/2008 Outperform NS $795.00 -93.53% +2.84% -96.37 4/17/2012 @ $51.40 0 Comment
TrackRBCCapMkts 86.95 3/5/2008 Outperform NS $782.97 -95.79% +107.77% -203.56 0 Comment
TrackCanaccord < 20 11/27/2007 Outperform NS $924.00 -96.43% +96.60% -193.04 0 Comment
TrackJimCramer 85.11 10/3/2007 Outperform 3W $1,155.00 -92.95% +36.45% -129.40 6/25/2015 @ $81.40 0 Comment
TrackBWS 97.27 8/1/2007 Outperform NS $630.00 -78.60% -41.38% -37.21 4/9/2009 @ $134.85 0 Comment
TrackRodmanRen < 20 1/24/2007 Outperform NS $753.00 -95.62% +98.53% -194.15 0 Comment

Featured Broker Partners